AGL — Agilon Health, Inc.

Summary of AGL Q3 2025 Earnings Call

1. Key Financial Results and Metrics:

• Revenue: $1.44 billion, slightly down from $1.45 billion in Q3 2024.
• Medical Margin: Negative $57 million, comparable to negative $58 million in Q3 2024.
• Adjusted EBITDA: Negative $91 million, an improvement from negative $96 million in Q3 2024.
• Membership: Medicare Advantage membership decreased to 503,000 from 525,000 year-over-year; ACO REACH membership fell to 115,000 from 132,000.
• 2025 Guidance: Revenue expected between $5.81 billion and $5.83 billion, medical margin projected between negative $5 million and negative $15 million, and adjusted EBITDA between negative $270 million and negative $245 million.

2. Strategic Updates and Business Highlights:

• Reinitiated 2025 guidance with a focus on executing clinical and quality programs and cost discipline.
• Enhanced data pipeline provides better visibility into risk scores and clinical data for 80% of members, expected to improve forecasting and operational performance.
• Strategic initiatives include a disciplined approach to payer contracting, aiming for improved economic terms and reduced exposure to Part D.
• Successful performance in ACO REACH with adjusted EBITDA of $18 million, highlighting the program's value.
• Ongoing development of clinical pathways for chronic conditions, with promising results in heart failure management and palliative care.

3. Forward Guidance and Outlook:

• Anticipated improvement in 2026 driven by macro factors like a 9% benchmark rate increase and better-aligned payer contracts.
• Expected operating cost reductions of $30 million in 2026 from restructuring and efficiency initiatives.
• While specific 2026 guidance is not provided, management expresses optimism based on current initiatives and market conditions.

4. Bad News, Challenges, or Points of Concern:

• Lower-than-expected risk adjustment contributions negatively impacted medical margin by approximately $150 million for 2025.
• Continued high costs from exited markets and a disciplined approach to membership growth may lead to reduced membership numbers, impacting revenue.
• The search for a permanent CEO is ongoing, with no timeline for completion, raising concerns about leadership stability during a critical transition period.
• Risks associated with contracting negotiations, where unfavorable terms could lead to reduced membership and potential financial impacts.

5. Notable Q&A Insights:

• Management acknowledged the impact of changes in the ACO REACH program and indicated potential shifts to more favorable models.
• Discussions around payer contracts revealed a disciplined approach, with a willingness to exit unprofitable arrangements, which may reduce membership but improve margins.
• The CEO search is progressing well, with a focus on finding a candidate aligned with the company’s strategic direction.
• Insights into medical cost trends highlighted ongoing challenges with inpatient and oncology drug costs, although first-half trends have improved.
• The company is optimistic about the impact of clinical programs on future savings, with plans to expand successful pilots into broader implementations in 2026.

Overall, while AGL faces challenges in the current environment, strategic initiatives and improved data capabilities are expected to position the company for better performance in 2026.